Maggot debridement therapy has enjoyed a long history of use in the treatment of lower-extremity wounds. [1] [2] [3] [4] After falling out of favor in the early part of the 20th century (largely owing to the advent of antibiotics), maggot debridement therapy was reintroduced in the latter part of the century when clinicians reported improvement in chronic wounds with incidental myiasis. 5 Since then, numerous studies have supported the potential efficacy of this therapy for chronic wounds. [6] [7] [8] [9] [10] Although maggot debridement therapy seems to be beneficial in the treatment of chronic wounds in Maggot Therapy in "Lower-Extremity Hospice" Wound Care
We sought to assess, in a case-control model, the potential efficacy of maggot debridement therapy in 60 nonambulatory patients (mean ± SD age, 72.2 ± 6.8 years) with neuroischemic diabetic foot wounds (University of Texas grade C or D wounds below the malleoli) and peripheral vascular disease. Twenty-seven of these patients (45%) healed during 6 months of review. There was no significant difference in the proportion of patients healing in the maggot debridement therapy versus control group (57% versus 33%). Of patients who healed, time to healing was significantly shorter in the maggot therapy than in the control group (18.5 ± 4.8 versus 22.4 ± 4.4 weeks). Approximately one in five patients (22%) underwent a high-level (above-the-foot) amputation. Patients in the control group were three times as likely to undergo amputation (33% versus 10%). Although there was no significant difference in infection prevalence in patients undergoing maggot therapy versus controls (80% versus 60%), there were significantly more antibiotic-free days during follow-up in patients who received maggot therapy (126.8 ± 30.3 versus 81.9 ± 42.1 days). Maggot debridement therapy reduces short-term morbidity in nonambulatory patients with diabetic foot wounds. general, we are unaware of any trials that have specifically focused on the use of this therapy for chronic diabetic foot wounds. In our experience, maggot debridement therapy may be of benefit in a subset of patients with diabetic foot wounds ("lower-extremity hospice" patients) who are nonambulatory with ischemic wounds not likely to benefit from lower-extremity bypass grafting or other surgical vascular intervention. This population, although small in the larger milieu of diabetic foot wound care, is nonetheless a very important component of many tertiarycare clinics and has been poorly studied. The purpose of this study was to assess, in a case-control model, the potential efficacy of maggot debridement therapy in nonambulatory patients with neuroischemic diabetic foot wounds.
Methods
This project, designed as a case-control model, was conducted at a large, referral-based diabetic foot clinic located in a university teaching institution (Southern Arizona Veterans Affairs Medical Center, Tucson). Institutional review board approval was obtained to conduct the study. We reviewed medical records from 60 patients with diabetes (mean ± SD age, 72.2 ± 6.8 years) who met the following criteria: 1) a diagnosis of diabetes by their primary-care physician, 2) the presence of a single wound of the foot, 3) the inability to walk without the use of a wheelchair or another assistive device, 4) a diagnosis of peripheral vascular disease without surgical intervention by the attending vascular surgery service, and 5) at least 6 months of reliable follow-up information. All wounds were classified as University of Texas grade C or D (wounds with ischemia or infection and ischemia). 11 Data were reviewed over a 3-year period for any patients who met these criteria and also received maggot debridement therapy, yielding 30 procedures. These patients were compared with 30 age-and sex-matched control patients receiving standard wound care, thus yielding a 1:1 case-control ratio.
Patients in the maggot debridement therapy and control groups were treated in a standardized manner according to the protocol followed in the highrisk diabetic foot clinic where treatment was rendered. Patients were excluded if they did not have a diagnosis of clinically significant vascular disease. Vascular status was evaluated using pedal pulse palpation. The diagnosis of ischemia was standardized in the facility where data were collected and was based on the absence of more than one foot pulse or a nonaudible signal on Doppler ultrasonography of the dorsalis pedis or posterior tibial pulses on the affected extremity. This method of evaluation, although arguably not as sensitive as other noninvasive methods, such as transcutaneous oximetry, segmental extremity pressure studies, and laser Doppler flowmetry, has the benefit of having been performed systematically on all patients in this study. [12] [13] [14] [15] Soft-tissue or bone infection was a clinical diagnosis made by the treating physician at the time of assessment. Per the standard protocol, the diagnosis of infection was consistent with the current criteria described by the International Working Group on the Diabetic Foot, 16 including the presence of purulence, advancing cellulitis, and two or more other local signs of inflammation.
We evaluated several outcome variables in this case-control model, including proportion healed and time to healing, proportion of infections, and number of antibiotic-free days during the 6-month review period. We also evaluated the proportion of patients undergoing amputations in the maggot debridement therapy and control groups. Healing was defined as complete epithelialization of the wound. To evaluate differences in continuous variables between the surgery and control groups, we used a Student t-test for parametric samples. To evaluate dichotomous variables, we used a χ 2 test. 17 All data are reported as mean ± SD unless otherwise stated.
Results
Descriptive characteristics of the study population are given in Table 1 . There were no significant differences in age (P = .6), gender prevalence (P = .99), duration of diabetes (P = .4), or wound size (P = .4) between the maggot debridement therapy group and those who did not receive such therapy.
Twenty-seven of these nonambulatory patients with peripheral vascular disease (45%) healed during the Note: Continuous data are given as mean ± SD.
6-month review. With the available numbers, there was not a significant difference in the proportion of patients healing in the maggot debridement therapy group versus the control group (57% versus 33%; P = .07).
Of the patients who healed, time to healing was significantly shorter in the maggot debridement therapy group than in those who did not receive larval therapy (18.5 ± 4.8 versus 22.4 ± 4.4 weeks; P = .04). Approximately one in five patients (22%) underwent a high-level (above-the-foot) amputation. Patients were approximately three times as likely to undergo amputation in the control group (33% versus 10%; P = .03; odds ratio, 3.3; 95% confidence interval, 1.1 to 10.9). In addition, although there was no significant difference in infection prevalence in the maggot debridement therapy versus control group (80% versus 60%; P = .09), there were significantly more antibiotic-free days during the 6 months of follow-up in patients who received maggot debridement therapy (126.8 ± 30.3 versus 81.9 ± 42.1 days; P = .0001) (Fig. 1) .
Discussion
The results of this study suggest that maggot debridement therapy may reduce short-term morbidity in nonambulatory patients with diabetic foot wounds. This is a population that has gone largely unstudied in the literature in the past generation, most likely for two major reasons. First, these patients, by virtue of their advanced age and nonambulatory status, are less likely to be functional members of society than are their younger ambulatory counterparts with diabetic foot wounds. Second, this subset of patients has been thought to occupy a small proportion of most clinics' wound-care populations.
We coined the term lower-extremity hospice to refer to these patients and to broadly outline goals for therapy. This population is the least likely to heal for a variety of reasons, including poor blood flow, poor nutrition, and advanced age. Because of poor response to conventional therapy, many physicians have considered using expensive, high-technology pharmaceuticals and devices in an effort to promote healing. We argue that this strategy not only is not cost-effective but also raises false hopes in the minds of patients, family members, and other members of the wound-care team. We contend that for this very small subset of the lower-extremity wound population, the overall goal is not wound healing but delaying the onset of infection and high-level amputation. The results of this study suggest that larvae may be ideally suited to this task.
The design of this study had significant limitations. As this was a case-control (retrospective) design, outcomes were subject to selection and treatment bias. This problem was somewhat mitigated by the fact that the clinic where patients were evaluated uses a method of assessment, operational definitions, and treatment that are standardized between the two attending clinicians' consulting services. One may also rightly question the definition of peripheral vascular disease in this study. This diagnosis was ultimately left up to the attending clinicians, who based their diagnosis on clinical and noninvasive vascular assessments. Although all of the patients were evaluated by the vascular surgery service, not all received a noninvasive or invasive examination. Clearly, any of these factors could have affected outcomes. However, the magnitude of the differences in the proportion of amputations and antibiotic-free days suggests a potential positive clinical impact of maggot debridement therapy that mandates further study in this population.
There was no significant difference between the maggot debridement therapy and control groups in the overall incidence of lower-extremity infection. However, there was a large difference in the number of antibiotic-free days between the two groups. Patients receiving maggot debridement therapy had significantly more antibiotic-free days than did those who did not. Although other projects have outlined bacteremia-free survival and other measurements, 18, 19 we are unaware of any study in the wound literature that has specifically evaluated this characteristic. In a previous large, longitudinal, population-based trial, Lavery et al 20 reported that during the life cycle of a wound, approximately 56% of patients will receive an antibiotic drug for treatment of infection (yielding an infection-ulcer ratio of 56%). This value does not, however, identify duration of therapy. Evaluation of antibiotic-free days acts as a surrogate marker for infection severity and wound chronicity.
